Exelixis Aktie
WKN: 936718 / ISIN: US30161Q1040
18.09.2021 06:11:20
|
FDA Approves Exelixis' Cabometyx To Treat Metastatic Differentiated Thyroid Cancer
(RTTNews) - The U.S. Food and Drug Administration approved Exelixis Inc.'s (EXEL) Cabometyx or cabozantinib for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor or VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
The FDA granted Breakthrough Therapy designation and Priority Review to Cabometyx and its approval comes more than two months ahead of the Prescription Drug User Fee Act (PDUFA) target action date of December 4, 2021.
The FDA approval was based on phase 3 COSMIC-311 pivotal trial, which demonstrated significant improvement in progression-free survival with Cabometyx versus placebo.
In the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced RCC; for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib; for patients with advanced RCC as a first-line treatment in combination with nivolumab; and for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
CABOMETYX tablets have also received regulatory approvals in the European Union and additional countries and regions worldwide.
In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan.
In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Exelixis Inc.mehr Nachrichten
27.05.25 |
NASDAQ Composite Index-Papier Exelixis-Aktie: So viel hätten Anleger an einem Exelixis-Investment von vor 5 Jahren verdient (finanzen.at) | |
20.05.25 |
NASDAQ Composite Index-Titel Exelixis-Aktie: So viel Gewinn hätte eine Exelixis-Investition von vor 3 Jahren eingebracht (finanzen.at) | |
15.05.25 |
Freundlicher Handel: NASDAQ Composite liegt im Plus (finanzen.at) | |
15.05.25 |
Zurückhaltung in New York: NASDAQ Composite liegt am Mittag im Minus (finanzen.at) | |
14.05.25 |
Freundlicher Handel in New York: NASDAQ Composite bewegt schlussendlich im Plus (finanzen.at) | |
14.05.25 |
NASDAQ-Handel: Börsianer lassen NASDAQ Composite nachmittags steigen (finanzen.at) | |
14.05.25 |
NASDAQ-Handel: NASDAQ Composite steigt am Mittwochmittag (finanzen.at) | |
14.05.25 |
Gute Stimmung in New York: NASDAQ Composite liegt zum Start im Plus (finanzen.at) |
Analysen zu Exelixis Inc.mehr Analysen
Aktien in diesem Artikel
Exelixis Inc. | 37,11 | 0,49% |
|